Synopsis
A study in Germany found that patients enrolled in a diabetes management program had significantly lower mortality rates than those receiving routine care for their condition. There were also fewer complications and hospitalizations and a significant difference in costs between baseline and intervention groups.
The Issue
In all countries, chronic health conditions pose major challenges to the health care system. Disease management programs have the potential to improve quality of care, increase patient satisfaction, and reduce costs, but their impact is still uncertain. For this study of nearly 20,000 enrollees in a diabetes management program in Germany—a country where more than 14 percent of total health spending is for diabetes care—researchers examined medical outcomes and costs over a four-year period (2003–2007) compared with control-group patients receiving routine care.
Key Findings
-
For patients enrolled in the disease management program, the overall mortality rate (2.30%) in 2007 was significantly lower than the rate for those in the control group (4.07%).
-
There were fewer complications—including myocardial infarction, stroke, chronic renal insufficiency, and amputation of the lower leg or foot—among patients in the program, compared with those receiving routine care.
-
Average overall drug and hospital costs in 2007 were more than $600 lower in the intervention group, mainly a result of lower hospital costs.
-
Patients receiving routine care were more likely to be hospitalized than patients in the intervention group, and their hospital stays were 1.44 days longer, on average.
Addressing the Problem
About the Study
The study assessed the effectiveness of a nationwide primary care disease management program for diabetes in the German health insurance system between 2003 and 2007. The sample included 19,882 patients with diabetes enrolled in the program and a control group of patients with diabetes receiving routine care.
The Bottom Line
A German disease management program reduced mortality, lowered costs, and improved health outcomes for patients with diabetes.